Loading...
01/11 03:18
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals financial struggles, with increased losses and minimal revenue from imaging systems. Despite some growth in AI solutions and teleradiology, profitability remains elusive. The lack of a shareholder return plan and unclear breakeven timeline further dampen sentiment. While there are positive developments like market expansion and regulatory achievements, the overall financial health and guidance provided are weak, leading to a likely negative stock price reaction.
GAAP Net Loss $13.2 million (increase of $1.0 million from $12.2 million in Q1 2024) due to an increase of $1.1 million in gross loss.
Revenue $2.8 million (increase of $0.2 million from $2.6 million in Q1 2024) attributed to growth in teleradiology services.
Gross Loss $3.0 million (increase of $0.9 million from $2.1 million in Q1 2024) on a GAAP basis.
Non-GAAP Gross Loss $0.4 million (decrease from a gross profit of $0.6 million in Q1 2024) representing a gross margin of approximately 15% compared to 22% in the comparable period.
Teleradiology Revenue $2.6 million (increase of $0.2 million from $2.4 million in Q1 2024) with a gross profit of $0.4 million, up from $0.3 million, reflecting customer retention, increased rates, and increased volume.
Teleradiology Non-GAAP Gross Profit $1.0 million (increase from $0.9 million in Q1 2024) representing a gross profit margin of approximately 39% compared to 37% in the comparable period.
Imaging Systems Revenue $33,000 (decrease from $47,000 in Q1 2024) with a gross loss of $1.16 million on a GAAP basis.
AI Solutions Revenue $0.2 million (increase from $0.1 million in Q1 2024) with a gross loss of $1.9 million on a GAAP basis.
Research and Development Expenses $5.0 million (decrease of $0.2 million from $5.2 million in Q1 2024) due to a decrease in share-based compensation and R&D activity expenses.
Sales and Marketing Expenses $0.9 million (increase from $0.8 million in Q1 2024).
General and Administrative Expenses $5.1 million (increase of $0.1 million from $5.0 million in Q1 2024) due to increases in salaries, IT expenses, and commercialization efforts.
Cash and Cash Equivalents Approximately $72.9 million as of March 31, 2025.
Short-term Loans $3.1 million from a bank.
Property and Equipment Net of $45.3 million as of March 31, 2025.
Shares Outstanding Approximately 63.8 million shares.
New Product Launch: The Nano-X ARC system is being deployed commercially, with over 60 units in various stages of implementation and execution.
AI Solutions: Nano-X AI is generating growing revenue and is a key part of the company's strategy to integrate AI into medical imaging.
Market Expansion: The company is expanding its market presence in the EU, with plans to ship demo units to Greece, Romania, and Mexico.
Sales Pipeline Growth: The sales pipeline has doubled since January 2025, with over 1,000 leads primarily from small and medium-sized health clinics globally.
Operational Efficiency: The average target of scans per day for operational units is seven, indicating effective utilization of the Nano-X ARC systems.
Sales Team Expansion: The sales team is being strengthened, with a target of 30 to 40 personnel by the end of 2025.
Strategic Partnerships: The company has formed distributor partnerships and is negotiating with additional national distributors.
New Project Development: A new project targeting the workers' compensation segment is in the finalization stages, with potential contractual rates of $120 to $180 per patient.
Earnings Miss: Nano-X Imaging Ltd. reported an EPS of $-0.21, missing expectations of $-0.19, indicating potential financial instability.
Regulatory Challenges: The introduction of new technology in the US market is challenging, requiring significant time and resources to educate prospective customers.
Market Uncertainties: Recent market uncertainties could impact the company's guidance and overall business performance.
Supply Chain Issues: The company is actively engaging with OEM partners to ensure adequate supply of components for the ARC system.
Competitive Pressures: The company faces competition in the medical imaging market, necessitating strong marketing and sales strategies to gain traction.
Financial Losses: The company reported a GAAP net loss of $13.2 million for Q1 2025, an increase from $12.2 million in Q1 2024, indicating ongoing financial challenges.
Revenue Generation: Revenue from imaging systems and OEM services was only $33,000, with a significant gross loss, highlighting difficulties in generating income from new products.
AI Solutions Performance: Despite some revenue growth in AI solutions, the segment still reported a gross loss of $1.9 million, indicating challenges in profitability.
Strategic Acquisitions: Nano-X made two strategic acquisitions in 2021: USARad (teleradiology) and Zebra Medical Vision (now Nano-X AI) to enhance their end-to-end solution.
Sales Pipeline Growth: The sales pipeline has doubled since January 2025, with over 1,000 leads primarily from small and medium-sized health clinics globally.
Deployment Targets: Targeting over 100 ARC systems in various stages of deployment by the end of 2025.
Distributor Partnerships: Expanded partnerships with distributors, including a non-exclusive agreement for sales to public health authorities in the US.
Workers' Compensation Project: Initiating a project to provide imaging services for the workers' compensation segment, with potential contractual rates of $120 to $180 per patient.
AI Solutions Growth: Strong interest and sales pipeline growth for AI solutions, with collaborations and pilot programs underway.
Revenue Expectations: Revenue for Q1 2025 was reported at $2.8 million, with expectations for growth driven by teleradiology and AI solutions.
Market Deployment: Progressing with the US deployment of Nano-X ARC, preparing to ship systems to Puerto Rico and expanding into EU markets.
Financial Projections: The company reported a GAAP net loss of $13.2 million for Q1 2025, with ongoing efforts to improve margins and revenue streams.
Hiring Plans: Plans to increase US personnel to 30-40 by the end of 2025 to support commercialization efforts.
Shareholder Return Plan: None
The earnings call presents mixed signals. The company shows revenue growth and improved gross margins in teleradiology services, but faces challenges with AI solutions and a slight net loss increase. The Q&A section reveals unclear management responses, especially regarding system deployment, raising concerns. Despite optimistic guidance for future breakeven and revenue targets, the absence of immediate catalysts and some operational uncertainties suggest a neutral stock price movement over the next two weeks.
The earnings call presents a mixed picture: slight revenue growth and strategic market expansion are positive, but increased losses and vague management responses in the Q&A section are concerning. The company's focus on AI and regulatory achievements offer long-term potential, but short-term financial metrics and execution risks temper optimism. With no clear guidance improvement, the stock is likely to remain stable in the near term.
The earnings call reveals financial struggles, with increased losses and minimal revenue from imaging systems. Despite some growth in AI solutions and teleradiology, profitability remains elusive. The lack of a shareholder return plan and unclear breakeven timeline further dampen sentiment. While there are positive developments like market expansion and regulatory achievements, the overall financial health and guidance provided are weak, leading to a likely negative stock price reaction.
The earnings call highlights several negative aspects: increased financial losses, minimal revenue generation, and lack of a shareholder return plan. While there are some positive indicators, such as regulatory achievements and market expansion plans, these are overshadowed by financial struggles and unclear guidance. The Q&A session reveals concerns about deployment delays and lack of clear break-even strategy. Despite some growth in teleradiology, the overall sentiment is negative due to increased losses and uncertainties, likely leading to a negative stock price reaction.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
